Six-month dual antiplatelet tx noninferior to 24-month DAPT

Six-month dual antiplatelet tx noninferior to 24-month DAPT
For aspirin-sensitive patients undergoing everolimus-eluting stent implantation, six-month dual antiplatelet therapy (DAPT) is noninferior to 24-month DAPT, according to a study published in the March 3 issue of the Journal of the American College of Cardiology.

(HealthDay)—For aspirin-sensitive patients undergoing everolimus-eluting stent implantation, six-month dual antiplatelet therapy (DAPT) is noninferior to 24-month DAPT, according to a study published in the March 3 issue of the Journal of the American College of Cardiology.

Martine Gilard, M.D., Ph.D., from Brest University in France, and colleagues examined whether antiplatelet treatment with DAPT for six months was noninferior to 24-month DAPT in patients who were aspirin sensitive. Patients undergoing implantation of everolimus-eluting stents with confirmed nonresistance to aspirin were randomized to receive six- or 24-month DAPT. Due to recruitment problems, the trial was terminated prematurely, with 941 patients randomized to 24-month DAPT and 953 to six-month DAPT.

The researchers found that at 12 months post-stenting, there was no significant between-group difference in the primary end point (composite of death, myocardial infarction, urgent target vessel revascularization, stroke, and major bleeding; 1.5 percent [24-month] versus 1.6 percent [six-month]; P = 0.85). Noninferiority was demonstrated for six-month DAPT, with an absolute risk difference of 0.11 percent (P for noninferiority = 0.0002). No significant differences were seen in stent thrombosis or bleeding complications. Primary and secondary end points did not differ for the 792 high-risk patients with (hazard ratio, 1.7; 95 percent confidence interval, 0.519 to 6.057; P = 0361).

"Rates of and thrombotic events were not significantly different according to six- versus 24-month DAPT after with new-generation drug-eluting stents in good responders," the authors write.

The study was partially funded by Abbott Vascular Devices.


Explore further

Results of the OPTIMIZE trial presented

More information: Full Text
Editorial (subscription or payment may be required)

Copyright © 2015 HealthDay. All rights reserved.

Citation: Six-month dual antiplatelet tx noninferior to 24-month DAPT (2015, February 25) retrieved 19 September 2019 from https://medicalxpress.com/news/2015-02-six-month-dual-antiplatelet-tx-noninferior.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
2 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more